MacroGenics Inc
MGNX1.620USD
-0.110-6.36%
收盘 09/19, 16:00（美东）报价延迟15分钟
102.39M总市值
亏损市盈率 TTM
关于 MacroGenics Inc 公司
MacroGenics, Inc. 是一家生物制药公司，专注于开发和商业化用于治疗癌症的单克隆抗体疗法。该公司的产品候选药物管线主要来自其基于抗体的技术平台套件，这些平台适用于广泛的治疗领域。该公司正在开发针对各种肿瘤相关抗原和免疫检查点分子的产品候选药物。其领先的管线项目是 vobramitamab duocarmazine (vobra duo)，这是一种抗体-药物偶联物 (ADC)，靶向 B7-H3，B7-H3 是 B7 家族免疫调节蛋白中的一种分子，由几种不同的肿瘤类型表达。其临床管线包括两种基于其双特异性 DART 技术的候选产品，该技术可同时与 PD-1 和其他检查点分子结合。这些候选药物包括 lorigerlimab 和 tebotelimab。此外，该公司正在开发双特异性 DART 分子 MGD024。该公司还在开发各种其他项目。
公司简介
公司代码MGNX
公司名称MacroGenics Inc
上市日期Oct 10, 2013
CEOMr. Eric Risser
员工数量341
证券类型Ordinary Share
年结日Oct 10
公司地址9704 Medical Center Drive
城市ROCKVILLE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编20850
电话13012515172
网址https://www.macrogenics.com/
公司代码MGNX
上市日期Oct 10, 2013
CEOMr. Eric Risser
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
111.00K
+909.09%
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Dr. Margaret A. Liu, M.D.
Dr. Margaret A. Liu, M.D.
Independent Director
Independent Director
11.00K
+144.44%
Dr. Ezio Bonvini, M.D.
Dr. Ezio Bonvini, M.D.
Senior Vice President - Research, Chief Scientific Officer
Senior Vice President - Research, Chief Scientific Officer
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Mr. Eric Risser
Mr. Eric Risser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Jeffrey Peters
Mr. Jeffrey Peters
Senior Vice President, General Counsel, Corporate Compliance Officer
Senior Vice President, General Counsel, Corporate Compliance Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
111.00K
+909.09%
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Dr. Margaret A. Liu, M.D.
Dr. Margaret A. Liu, M.D.
Independent Director
Independent Director
11.00K
+144.44%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月17日 周日
更新时间: 8月17日 周日
持股股东
股东类型
持股股东
持股股东
占比
Bellevue Asset Management AG
15.69%
Armistice Capital LLC
9.43%
The Vanguard Group, Inc.
6.67%
Wasatch Global Investors Inc
5.14%
Frazier Life Sciences Management, L.P.
5.02%
其他
58.04%
持股股东
持股股东
占比
Bellevue Asset Management AG
15.69%
Armistice Capital LLC
9.43%
The Vanguard Group, Inc.
6.67%
Wasatch Global Investors Inc
5.14%
Frazier Life Sciences Management, L.P.
5.02%
其他
58.04%
股东类型
持股股东
占比
Investment Advisor
28.94%
Investment Advisor/Hedge Fund
19.39%
Hedge Fund
18.93%
Private Equity
5.02%
Research Firm
4.21%
Individual Investor
3.34%
Pension Fund
0.11%
Venture Capital
0.02%
其他
20.03%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
349
54.16M
85.84%
-24.12M
2025Q1
365
56.04M
88.82%
-21.64M
2024Q4
367
57.72M
91.98%
-20.16M
2024Q3
367
57.51M
91.64%
-21.39M
2024Q2
370
63.01M
100.47%
-16.59M
2024Q1
368
67.02M
107.12%
-8.36M
2023Q4
353
64.08M
103.25%
-12.72M
2023Q3
352
60.31M
97.24%
-15.19M
2023Q2
356
62.23M
100.48%
-18.91M
2023Q1
389
60.87M
98.46%
-22.53M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Bellevue Asset Management AG
9.93M
15.74%
--
--
Jun 01, 2025
Armistice Capital LLC
6.30M
9.98%
+20.00K
+0.32%
Mar 31, 2025
The Vanguard Group, Inc.
4.43M
7.02%
+109.31K
+2.53%
Mar 31, 2025
Wasatch Global Investors Inc
3.25M
5.15%
-238.25K
-6.83%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
3.18M
5.03%
--
--
Mar 31, 2025
Acadian Asset Management LLC
2.31M
3.66%
+1.02M
+78.84%
Mar 31, 2025
Millennium Management LLC
1.72M
2.73%
-1.14M
-39.81%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.50M
7.13%
-147.34K
-3.17%
Mar 31, 2025
Koenig (Scott)
1.37M
2.18%
+427.48K
+45.23%
Mar 24, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
